Second-line treatment with Axitinib: an effective and well-tolerated weapon in the therapeutic sequence of clear cell renal cell carcinoma

In recent years, renal cancer has seen a continuous and rapid increase in the number of cases, with a trend that is destined to increase: it is estimated that in the next 20 years there will be an increase in incidence of about 25% more than today. More than a quarter of patients with renal neoplasia present at diagnosis with advanced disease. The treatment of advanced renal cancer has seen in recent years the development and subsequent approval and marketing of at least seven new drugs, which have characterized the transition of this neoplasm from a condition of "orphan" disease due to the small number of therapeutic options available to a sort of "in vivo model" for the development of new molecularly targeted drugs. In this evolving scenario, effectively defined as "an increased entropy" in the treatment of metastatic renal cell carcinoma, the rational use of the therapeutic weapons at our disposal through defined sequential and personalized strategies is the fundamental prerequisite to maximize the effectiveness and improve the survival of these patients, which today is over 30 months.